Alzheimer's in CNY doesn’t need to be so “agitating”

crystal destefano
Tuesday, June 8, 2021

Alzheimer's in CNY doesn’t need to be so “agitating”

 

Syracuse, NY (June 8, 2021) – Central New Yorkers will have something new to celebrate during this year’s Alzheimer’s & Brain Awareness Month, which began June 1st.

 

Clarity Clinical Research in East Syracuse is part of a new national research study of an investigational oral medication to see if it can reduce symptoms of agitation in people with Alzheimer’s disease.

 

“It has been reported that 70% of people with Alzheimer’s display agitation and aggression,” said Lisa Sonneborn, Site Director at Clarity Clinical Research. “Agitation makes caring for a loved one with Alzheimer's disease more difficult, and research has shown that not treating these symptoms may actually increase the risk of faster cognitive decline.”

 

During the COVID-19 pandemic, Sonneborn’s team has seen a significant increase in outreach from local caregivers looking for support, especially as they struggle to care for their loved one who is at home and agitated.

 

The ACCORD Study (accord-study.com) is working with Clarity Clinical Research in Syracuse and other research sites across the country to address the underlying cause of these issues. “We need to accelerate this research to help our community members who are fighting this battle,” Sonneborn said.

 

Examples of agitation include:

  • Rapid changes in mood
  • Irritability or outbursts
  • Physical or verbal aggression
  • Excessive motor activity (pacing, rocking, gesturing, etc.)

 

“Caregivers for Alzheimer’s disease patients do everything possible to create a calm environment and mitigate potential triggers, but even the best environment can’t prevent this incredibly disruptive agitation for some patients. It’s emotionally heartbreaking for both the caregiver and the patient,” Sonneborn explained. “This new study could help us tackle these agitation symptoms from the inside, potentially reducing this horrible experience for Alzheimer’s patients and their caregivers while we continue to seek a cure for the disease.”

 

The investigational medication targets different central nervous system receptor systems and it has already received Breakthrough Therapy Designation from the FDA for both Alzheimer’s Disease agitation as well as Major Depressive Disorder.

 

Alzheimer’s disease patients who experience symptoms of agitation may be eligible for this study, which is open for enrollment today at Clarity Clinical Research. Participants in this research study may receive:

 

  • Regular monitoring and assessment of their Alzheimer’s-related agitation symptoms
  • Study-related care and investigational study medication at no cost
  • Compensation for time and travel to attend periodic visits at your study doctor’s office for up to 9 months.

 

Caregivers can visit www.clarityclinicalresearch.com to request more information or call 315-760-5905 x 702.